Nanobiotix (NBTX) has released an update.
Nanobiotix, a pioneering biotech firm, has updated its total number of shares and voting rights, emphasizing its commitment to revolutionary, physics-based therapies. With a focus on oncology, bioavailability, and central nervous system disorders, the company has a robust portfolio of over 25 patent families. Nanobiotix is listed on both Euronext Paris and the Nasdaq Global Select Market, reflecting its international presence and growth trajectory.
For further insights into NBTX stock, check out TipRanks’ Stock Analysis page.
